PD-1 INHIBITOR
Clinical trials for PD-1 INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new PD-1 INHIBITOR trials appear
Sign up with your email to follow new studies for PD-1 INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two-Drug combo aims to wipe out rectal cancer before surgery
Disease control Not yet recruitingThis trial investigates whether adding two targeted drugs—tafolecimab and sintilimab—to standard chemoradiation can improve outcomes for people with locally advanced rectal cancer that has not spread. Participants receive short-course radiation followed by chemotherapy plus immun…
Matched conditions: PD-1 INHIBITOR
Phase: PHASE3 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New triple therapy hopes to outsmart tough esophageal cancer
Disease control Not yet recruitingThis study tests a new combination of three drugs—becotatug vedotin, tislelizumab, and chemotherapy—for people with advanced esophageal squamous cell carcinoma (ESCC) who have not had prior treatment. The goal is to see if adding the targeted drug becotatug vedotin to standard im…
Matched conditions: PD-1 INHIBITOR
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Radiation plus immunotherapy: a new hope for rectal cancer patients?
Disease control Not yet recruitingThis phase 2 trial is testing a new approach for people with stage II-III rectal cancer. It combines short-course radiotherapy that spares the tumor-draining lymph nodes with a PD-1 inhibitor (a type of immunotherapy). The goal is to see if this combination can lead to a complete…
Matched conditions: PD-1 INHIBITOR
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC